Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting_老虎社区_美港股上老虎

Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting

seekingalpha2023-11-07

Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

赢击长空
·2023-11-17
吹牛逼，说好2期数据呢
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2381014751?lang=zh_CN&edition=full","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/977304138/image_977304138.jpg","is_english":true,"pubTime":"2023-11-07 00:38","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2381014751","market":"us","top_or_hot":-1,"title":"Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting","media":"seekingalpha","content":"<div>\n<p>Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccitech rebrands as Barinthus, plans to present data at AASLD meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-07 00:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QQQ","symbol_name":"纳指100ETF","start_time":0,"source_url":"https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting","article_id":"2381014751","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/977304138/image_977304138.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2381014751","pubTimestamp":1699288734,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Vaccitech  said that it has rebranded at Barinthus Biotherapeutics  to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7. The company added that it plans to present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston.   More on Vaccitech  Vaccitech surges despite Morgan Stanley downgrade Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QQQ":"纳指100ETF","SQQQ":"纳指三倍做空ETF","LU0106831901.USD":"贝莱德世界金融基金A2","BK4539":"次新股",".IXIC":"NASDAQ Composite","LU0971096721.USD":"富达环球金融服务 A","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","MS":"摩根士丹利","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4588":"碎股","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","QID":"纳指两倍做空ETF","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","PSQ":"纳指反向ETF","BK4504":"桥水持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","TQQQ":"纳指三倍做多ETF","BRNS":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4127":"投资银行业与经纪业","QLD":"纳指两倍做多ETF"},"translate_title":"Vaccitech更名为Barinthus，计划在AASLD会议上展示数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACC":1,"BRNS":1,"MS":0.9,".IXIC":0.63,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"TQQQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7. The company added that it plans to present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston.   More on Vaccitech  Vaccitech surges despite Morgan Stanley downgrade Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":242523373674776,"gmtCreate":1700231026773,"gmtModify":1700231127716,"author":{"id":"3550916429756056","authorId":"3550916429756056","name":"赢击长空","avatar":"https://static.tigerbbs.com/d67d618b2a23c914580657c77ce712c1","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"吹牛逼，说好2期数据呢","listText":"吹牛逼，说好2期数据呢","text":"吹牛逼，说好2期数据呢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/242523373674776","repostId":2381014751,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}